The design and synthesis of a potentially more therapeutically-viable azinomycin analogue 4 based upon 3 has been completed. It involved coupling of a piperidine mustard to the acid chloride of the azinomycin chromophore. Both the designed azinomycin analogue 4 and the natural product 3 bind to DNA and cause unwinding, supporting an intercalative mode of binding. (C) 2004 Elsevier Ltd. All rights reserved
Mitomycin C (MC) is a naturally occurring alkylating agent used as an anticancer drug for its abilit...
Mitomycin C (MC) is a clinically administered cancer therapy agent that forms interstrand crosslinks...
Aziridinomitosenes are synthetic derivatives of the antitumoral/antibiotic drug mitomycin C, a compo...
The design and synthesis of a potentially more therapeutically-viable azinomycin analogue 4 based up...
NoThe design and synthesis of a potentially more therapeutically-viable azinomycin analogue 4 based ...
The azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relatively...
NoThe azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relative...
Nature is a rich source of antitumour agents that can act as a paradigm for the development of synth...
Several common cancer-fighting therapies such as Mitomycin (MC) function by binding DNA strands to f...
Aziridinomitosenes (AZMs) are being synthesized to explore their ability to alkylate DNA. AZMs coval...
Mitomycin C (MC) is a quinone containing anti-cancer agent that alkylates DNA, forming insterstrand ...
Bifunctional alkylating agents such as chlorambucil and melphalan represent an important class of cl...
Mitomycin C (MC), a quinone-containing cancer therapy agent, is biologically active by alkylating DN...
A new set of charges specifically developed for biologically relevant N7-alkylated purine adducts ha...
In this work, we present molecular modeling studies carried out using six DNA sequences and six azin...
Mitomycin C (MC) is a naturally occurring alkylating agent used as an anticancer drug for its abilit...
Mitomycin C (MC) is a clinically administered cancer therapy agent that forms interstrand crosslinks...
Aziridinomitosenes are synthetic derivatives of the antitumoral/antibiotic drug mitomycin C, a compo...
The design and synthesis of a potentially more therapeutically-viable azinomycin analogue 4 based up...
NoThe design and synthesis of a potentially more therapeutically-viable azinomycin analogue 4 based ...
The azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relatively...
NoThe azinomycins are potent antitumour antibiotics that are able to crosslink DNA, but are relative...
Nature is a rich source of antitumour agents that can act as a paradigm for the development of synth...
Several common cancer-fighting therapies such as Mitomycin (MC) function by binding DNA strands to f...
Aziridinomitosenes (AZMs) are being synthesized to explore their ability to alkylate DNA. AZMs coval...
Mitomycin C (MC) is a quinone containing anti-cancer agent that alkylates DNA, forming insterstrand ...
Bifunctional alkylating agents such as chlorambucil and melphalan represent an important class of cl...
Mitomycin C (MC), a quinone-containing cancer therapy agent, is biologically active by alkylating DN...
A new set of charges specifically developed for biologically relevant N7-alkylated purine adducts ha...
In this work, we present molecular modeling studies carried out using six DNA sequences and six azin...
Mitomycin C (MC) is a naturally occurring alkylating agent used as an anticancer drug for its abilit...
Mitomycin C (MC) is a clinically administered cancer therapy agent that forms interstrand crosslinks...
Aziridinomitosenes are synthetic derivatives of the antitumoral/antibiotic drug mitomycin C, a compo...